Recent progress on tyrosine kinase 2 JH2 inhibitors

被引：7

作者：

Deng, Lidan ^{[1
]}

Wan, Li ^{[1
]}

Liao, Tingting ^{[2
]}

Wang, Lin ^{[3
]}

Wang, Jie ^{[4
]}

Wu, Xianbo ^{[1
]}

Shi, Jianyou ^{[1
,5
,6
,7
]}

机构：

[1] Chengdu Sport Univ, Sch Sports Med & Hlth, Chengdu 610041, Sichuan, Peoples R China

[2] Hosp Chengdu Univ Tradit Chinese Med, Chengdu 610072, Sichuan, Peoples R China

[3] Xihua Univ, Coll Food & Bioengn, Chengdu 610039, Peoples R China

[4] Guizhou Univ Tradit Chinese Med, Guiyang 550002, Guizhou, Peoples R China

[5] Univ Elect Sci & Technol China, Sichuan Acad Med Sci, Dept Pharm,Sch Med, Personalized Drug Therapy Key Lab Sichuan Prov, Chengdu 610072, Sichuan, Peoples R China

[6] Univ Elect Sci & Technol China, Sichuan Prov Peoples Hosp, Sch Med, Chengdu 610072, Sichuan, Peoples R China

[7] Chengdu Univ Tradit Chinese Med, State Key Lab Southwestern Chinese Med Resources, Chengdu 611137, Peoples R China

来源：

INTERNATIONAL IMMUNOPHARMACOLOGY | 2023年 / 121卷

基金：

中国国家自然科学基金;

关键词：

Tyrosine kinase 2 (TYK2); JH2; inhibitor; Autoimmune diseases; Deucravacitinib; BMS-986202; SYSTEMIC-LUPUS-ERYTHEMATOSUS; PSORIATIC-ARTHRITIS; CLINICAL-FEATURES; JAK INHIBITORS; JANUS KINASES; IMMUNE; MECHANISMS; DISCOVERY; STATS; EPIDEMIOLOGY;

D O I：

10.1016/j.intimp.2023.110434

中图分类号：

R392 [医学免疫学]; Q939.91 [免疫学];

学科分类号：

100102 ;

摘要：

Tyrosine kinase 2 (TYK2) is a member of the Janus kinase (JAK) family, which can regulate the signaling of multiple pro-inflammatory cytokines, including IL12, IL23 and type I interferon (IFN & alpha;/& beta;), and its inhibitors can treat autoimmune diseases caused by the abnormal expression of IL12 and IL23. Interest in TYK2 JH2 inhibitors has increased as a result of safety concerns with JAK inhibitors. This overview introduces TYK2 JH2 inhibitors that are already on the market, including Deucravactinib (BMS-986165), as well as those currently in clinical trials, such as BMS-986202, NDI-034858, and ESK-001.

引用

页数：10

共 50 条

[31] Cardiovascular toxicity of tyrosine kinase inhibitors
Mouhayar, Elie
Durand, Jean-Bernard
Cortes, Jorge
EXPERT OPINION ON DRUG SAFETY, 2013, 12 (05) : 687 - 696
[32] Recent Progress tort the Discovery of Sirt2 Inhibitors for the Treatment of Various Cancers
Wang, Ting
Xu, Zhuyu
Lu, Yongping
Shi, Jianyou
Liu, Wenbo
Zhang, Chengchen
Jiang, Zhongliang
Qi, Baowen
Bai, Lan
CURRENT TOPICS IN MEDICINAL CHEMISTRY, 2019, 19 (12) : 1051 - 1058
[33] Recent progress in development of cyclin-dependent kinase 7 inhibitors for cancer therapy
Liang, Hanzhi
Du, Jintong
Elhassan, Reham M.
Hou, Xuben
Fang, Hao
EXPERT OPINION ON INVESTIGATIONAL DRUGS, 2021, 30 (01) : 61 - 76
[34] QSAR and molecular docking studies on oxindole derivatives as VEGFR-2 tyrosine kinase inhibitors
Kang, Cong-Min
Liu, Dong-Qing
Zhao, Xu-Hao
Dai, Ying-Jie
Cheng, Jia-Gao
Lv, Ying-Tao
JOURNAL OF RECEPTORS AND SIGNAL TRANSDUCTION, 2016, 36 (01) : 103 - 109
[35] Identification of new pyrrolo[2,3-d]pyrimidines as Src tyrosine kinase inhibitors in vitro active against Glioblastoma
Musumeci, Francesca
Fallacara, Anna Lucia
Brullo, Chiara
Grossi, Giancarlo
Botta, Lorenzo
Calandro, Pierpaolo
Chiariello, Mario
Kissova, Miroslava
Crespan, Emmanuele
Maga, Giovanni
Schenone, Silvia
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY, 2017, 127 : 369 - 378
[36] A modified JH2 model with improved strength model, damage evolution, and equation of state for rock under impact and blasting loads
Shu, Yun
Zhu, Zheming
Wang, Meng
Wang, Fei
Ren, Li
Li, Yaojia
MECHANICS OF MATERIALS, 2022, 174
[37] Inhibitors of the tyrosine kinase EphB4. Part 3: Identification of non-benzodioxole-based kinase inhibitors
Bardelle, Catherine
Barlaam, Bernard
Brooks, Nigel
Coleman, Tanya
Cross, Darren
Ducray, Richard
Green, Isabelle
Lambert-van der Brempt, Christine
Olivier, Annie
Read, Jon
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2010, 20 (21) : 6242 - 6245
[38] Uncoupling JAK2 V617F activation from cytokine-induced signalling by modulation of JH2 αC helix
Leroy, Emilie
Dusa, Alexandra
Colau, Didier
Motamedi, Amir
Cahu, Xavier
Mouton, Celine
Huang, Lily J.
Shiau, Andrew K.
Constantinescu, Stefan N.
BIOCHEMICAL JOURNAL, 2016, 473 : 1579 - 1591
[39] Progress in the development of small molecular inhibitors of the Bruton's tyrosine kinase (BTK) as a promising cancer therapy
Liu, Xiu-Juan
Liu, Xu
Pang, Xiao-Jing
Yuan, Xin-Ying
Yu, Guang-Xi
Li, Yin-Ru
Guan, Yong-Feng
Zhang, Yan-Bing
Song, Jian
Zhang, Qiu-Rong
Zhang, Sai-Yang
BIOORGANIC & MEDICINAL CHEMISTRY, 2021, 47
[40] 2-Thioxothiazolidin-4-one Analogs as Pan-PIM Kinase Inhibitors
Yun, Yanghwan
Hong, Victor Sukbong
Jeong, Seungik
Choo, Hyeonseong
Kim, Shin
Lee, Jinho
CHEMICAL & PHARMACEUTICAL BULLETIN, 2021, 69 (09) : 854 - 861

← 1 2 3 4 5 →